Literature DB >> 11789558

Clinical and pathological significance of vitamin D receptor gene polymorphism for prostate cancer which is associated with a higher mortality in Japanese.

T Hamasaki1, H Inatomi, T Katoh, T Ikuyama, T Matsumoto.   

Abstract

The purpose of this study was to investigate the TaqI vitamin D receptor (VDR) polymorphism in both Japanese prostate cancer patients and Japanese noncancer controls in order to determine if an association exists between VDR genotype with clinical and pathological risk of prostate cancer patients. This study involved 115 patients with prostate cancer and 133 male age-matched noncancer controls genotyped for a previously described TaqI restriction fragment length polymorphism (RFLP) at codon 352 in exon 9 of the VDR gene. Products were digested into T allele or t allele according to the absence or presence of TaqI restriction site with individuals being classified as TT, Tt, or tt. The genotype tt was higher among the control group (6.0%) compared to the patients with prostate cancer (1.8%), but not so (OR=0.28; 95%o CI, 0.06-1.33; p=0.081). In addition, the genotype TT was statistically higher among patients with locally advanced or metastatic disease (T3/T4/NI/M1) compared to controls (OR=2.52; 95%o CI, 1.21-5.27; p=0.009). Lastly, the genotype TT was statistically higher among patients with poorly differentiated adenocarcinoma compared to controls (OR=5.38; 95%o CI, 1.57-18.50; p=0.002). These data demonstrate that VDR genotype plays an important role in determining the risk of more clinically advanced and pathologically aggressive prostate cancer which is associated with a higher mortality rate in Japanese men.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11789558     DOI: 10.1507/endocrj.48.543

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  9 in total

1.  Association between bone mineral density and lifestyle factors or vitamin D receptor gene polymorphism in adult male workers: a cross-sectional study.

Authors:  Yayoi Funakoshi; Hisamitsu Omori; Takahiko Katoh
Journal:  Environ Health Prev Med       Date:  2009-08-25       Impact factor: 3.674

Review 2.  The role of vitamin D in cancer prevention.

Authors:  Cedric F Garland; Frank C Garland; Edward D Gorham; Martin Lipkin; Harold Newmark; Sharif B Mohr; Michael F Holick
Journal:  Am J Public Health       Date:  2005-12-27       Impact factor: 9.308

3.  Association of genetic polymorphisms in the interleukin-10 promoter with risk of prostate cancer in Chinese.

Authors:  Jie Liu; Bao Song; Xueli Bai; Wenjian Liu; Zengjun Li; Jialin Wang; Yan Zheng; Zhehai Wang
Journal:  BMC Cancer       Date:  2010-08-24       Impact factor: 4.430

4.  Association of VDR polymorphisms ( Taq I and Bsm I) with prostate cancer: a new meta-analysis.

Authors:  Sheng Liu; Hairong Cai; Weisong Cheng; Haitao Zhang; Zhengbo Pan; Dongguo Wang
Journal:  J Int Med Res       Date:  2017-01-17       Impact factor: 1.671

5.  Vitamin D receptor Taq I polymorphism and the risk of prostate cancer: a meta-analysis.

Authors:  Shaosan Kang; Yansheng Zhao; Lei Wang; Jian Liu; Xi Chen; Xiaofeng Liu; Zhijie Shi; Weixing Gao; Fenghong Cao
Journal:  Oncotarget       Date:  2017-12-22

6.  Association of VDR gene TaqI polymorphism with the susceptibility to prostate cancer in Asian population evaluated by an updated systematic meta-analysis.

Authors:  Liangliang Chen; Junjun Wei; Shuwei Zhang; Zhongguan Lou; Xue Wang; Yu Ren; Honggang Qi; Zhenhua Xie; Yirun Chen; Feng Chen; Qihang Wu; Xiaoxiao Fan; Honglei Xu; Shuaishuai Huang; Guobin Weng
Journal:  Onco Targets Ther       Date:  2018-05-31       Impact factor: 4.147

7.  A novel polymorphism in the 1A promoter region of the vitamin D receptor is associated with altered susceptibilty and prognosis in malignant melanoma.

Authors:  J A Halsall; J E Osborne; L Potter; J H Pringle; P E Hutchinson
Journal:  Br J Cancer       Date:  2004-08-16       Impact factor: 7.640

8.  Polymorphisms of vitamin D receptor gene TaqI susceptibility of prostate cancer: a meta-analysis.

Authors:  Xiawei Fei; Nannan Liu; Huifeng Li; Yanting Shen; Jianming Guo; Zhenqi Wu
Journal:  Onco Targets Ther       Date:  2016-03-01       Impact factor: 4.147

9.  CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia.

Authors:  M T Tayeb; C Clark; N E Haites; L Sharp; G I Murray; H L McLeod
Journal:  Br J Cancer       Date:  2003-03-24       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.